QSAM Biosciences Ret. on assets

What is the Ret. on assets of QSAM Biosciences?

The Ret. on assets of QSAM Biosciences, Inc. is -476.44%

What is the definition of Ret. on assets?



Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.

ttm (trailing twelve months)

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. on assets of companies in the Health Care sector on OTC compared to QSAM Biosciences

What does QSAM Biosciences do?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Companies with ret. on assets similar to QSAM Biosciences